| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 7,077,332 |
| Net loss | -49,132,094 |
| Prepaid expenses and other current assets | -6,171,166 |
| Other assets | 95,246 |
| Operating lease liabilities | -37,124 |
| Inventory | 4,126,716 |
| Accrued expenses | 1,355,493 |
| Accounts receivable | 1,751,422 |
| Accounts payable | 1,635,794 |
| Loss on equity method investment | -100,588 |
| Gain from change in fair value of warrant liability | -40,333,145 |
| Amortization | 87,315 |
| Warrant inducement expenses (note 9) | 33,856,814 |
| Loss from change in fair value of promissory notes | 5,739,005 |
| Net cash used in operating activities | -39,452,240 |
| Repayment of debt | 33,817,005 |
| Proceeds from exercise of common stock warrants | 16,831,132 |
| Proceeds from debt | 33,100,000 |
| Proceeds from the sale of common stock and warrants to purchase common stock, net of issuance costs | 17,311,389 |
| Net cash provided by financing activities | 33,425,516 |
| Net (decrease) increase in cash and cash equivalents | -6,026,724 |
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)